Substituted quinoxaline DNA-PK inhibitors

US10973830B2 · kind B2 · utility

Assignee

• Vertex Pharmaceuticals Incorporated · US

Inventors

• John Patrick Maxwell · Hingham, US
• Paul S. Charifson · Framingham, US
• Qing Tang · Acton, US
• Steven Ronkin · Watertown, US
• Katrina Lee Jackson · Cambridge, US
• Albert Pierce · Cambridge, US
• David J. Lauffer · Saline, US
• Pan Li · Lexington, US
• Simon Giroux · Cambridge, US
• Jinwang Xu · Framingham, US
• Kevin Michael Cottrell · Cambridge, US
• Mark A. Morris · Somerville, US
• Nathan D. Waal · Cambridge, US
• John J. Court · Littleton, US
• Wenxin Gu · Concord, US
• Hongbo Deng · Southborough, US

Key dates

• Filing date: Apr 1, 2019
• Grant date: Apr 13, 2021
• Expiry date: Apr 1, 2039

Classification

• Technology area (CPC C): Chemistry; Metallurgy
• CPC primary: C07D513/04
• WIPO field: Pharmaceuticals
• WIPO sector: Chemistry

Abstract

The present invention relates to Provided are compounds of Formula (I): wherein R1, R2, X, Ring A, Ring B, and Ring C are as defined herein. Compounds of Formula (I) are useful as inhibitors of DNA-PK. Also provided are pharmaceutical compositions comprising said compounds and methods of using the compounds and compositions in the treatment of various diseases, conditions, and disorders.